Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Editas Medicine Inc Is A Clinical-Stage Genome Editing Company Dedicated To Developing Potentially Transformative Genomic Medicines To Treat A Broad Range Of Serious Diseases. The Company Focuses On Developing A Proprietary Gene Editing Platform Based On Crispr Technology And Continues To Expand Its Capabilities. Crispr Uses A Protein-Rna Complex Composed Of An Enzyme, Including Either Cas9 (Crispr-Associated Protein 9) Or Cas12a (Crispr From Prevotella And Francisella 1, Also Known As Cpf1). The Company Has A Single Operating Segment, Which Is The Business Of Developing And Commercializing Gene Editing Technology.